APLS
Price
$20.07
Change
-$0.26 (-1.28%)
Updated
Jan 15, 11:10 AM (EDT)
Capitalization
2.57B
48 days until earnings call
Intraday BUY SELL Signals
CLDX
Price
$25.40
Change
-$0.94 (-3.57%)
Updated
Jan 15, 11:18 AM (EDT)
Capitalization
1.75B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APLS vs CLDX

Header iconAPLS vs CLDX Comparison
Open Charts APLS vs CLDXBanner chart's image
Apellis Pharmaceuticals
Price$20.07
Change-$0.26 (-1.28%)
Volume$700
Capitalization2.57B
Celldex Therapeutics
Price$25.40
Change-$0.94 (-3.57%)
Volume$300
Capitalization1.75B
APLS vs CLDX Comparison Chart in %
View a ticker or compare two or three
VS
APLS vs. CLDX commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (APLS: $20.33 vs. CLDX: $26.34)
Brand notoriety: APLS and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 222% vs. CLDX: 157%
Market capitalization -- APLS: $2.57B vs. CLDX: $1.75B
APLS [@Biotechnology] is valued at $2.57B. CLDX’s [@Biotechnology] market capitalization is $1.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, APLS is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while CLDX’s TA Score has 4 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 5 bearish.
  • CLDX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both APLS and CLDX are a good buy in the short-term.

Price Growth

APLS (@Biotechnology) experienced а -23.25% price change this week, while CLDX (@Biotechnology) price change was -5.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.23%. For the same industry, the average monthly price growth was +2.54%, and the average quarterly price growth was +43.40%.

Reported Earning Dates

APLS is expected to report earnings on Mar 04, 2026.

CLDX is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-0.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.57B) has a higher market cap than CLDX($1.75B). CLDX YTD gains are higher at: -3.019 vs. APLS (-19.068). APLS has higher annual earnings (EBITDA): 93.4M vs. CLDX (-252.86M). CLDX has more cash in the bank: 583M vs. APLS (479M). CLDX has less debt than APLS: CLDX (2.62M) vs APLS (475M). APLS has higher revenues than CLDX: APLS (1.02B) vs CLDX (2.6M).
APLSCLDXAPLS / CLDX
Capitalization2.57B1.75B147%
EBITDA93.4M-252.86M-37%
Gain YTD-19.068-3.019632%
P/E Ratio56.44N/A-
Revenue1.02B2.6M39,092%
Total Cash479M583M82%
Total Debt475M2.62M18,123%
FUNDAMENTALS RATINGS
APLS vs CLDX: Fundamental Ratings
APLS
CLDX
OUTLOOK RATING
1..100
6011
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
5797
PRICE GROWTH RATING
1..100
6458
P/E GROWTH RATING
1..100
59100
SEASONALITY SCORE
1..100
5042

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (69) in the Biotechnology industry is in the same range as APLS (83) in the Medical Distributors industry. This means that CLDX’s stock grew similarly to APLS’s over the last 12 months.

CLDX's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CLDX’s stock grew similarly to APLS’s over the last 12 months.

APLS's SMR Rating (57) in the Medical Distributors industry is somewhat better than the same rating for CLDX (97) in the Biotechnology industry. This means that APLS’s stock grew somewhat faster than CLDX’s over the last 12 months.

CLDX's Price Growth Rating (58) in the Biotechnology industry is in the same range as APLS (64) in the Medical Distributors industry. This means that CLDX’s stock grew similarly to APLS’s over the last 12 months.

APLS's P/E Growth Rating (59) in the Medical Distributors industry is somewhat better than the same rating for CLDX (100) in the Biotechnology industry. This means that APLS’s stock grew somewhat faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCLDX
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 11 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signal:
Gain/Loss:
CLDX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HMSIX12.580.10
+0.80%
Hennessy Midstream Institutional
MOPCX22.750.17
+0.75%
NYLI WMC Small Companies Class C
MMPCX20.890.15
+0.72%
NYLI WMC Value Class C
RIGFX46.790.17
+0.36%
American Funds Intl Gr and Inc R5
GERAX11.940.01
+0.08%
Goldman Sachs Em Mkts Eq Insghts A

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NUVL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-4.69%
NUVL - APLS
38%
Loosely correlated
+6.59%
BBIO - APLS
36%
Loosely correlated
-1.53%
ALNY - APLS
35%
Loosely correlated
-0.84%
CLDX - APLS
35%
Loosely correlated
+1.58%
REPL - APLS
34%
Loosely correlated
-4.10%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KURA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+1.58%
KURA - CLDX
56%
Loosely correlated
+1.63%
VIR - CLDX
55%
Loosely correlated
+8.08%
XNCR - CLDX
55%
Loosely correlated
+3.66%
VRDN - CLDX
54%
Loosely correlated
+5.60%
NUVL - CLDX
52%
Loosely correlated
+6.59%
More